RxDoctor Payments Data

Audrey Garrett

Gynecologic Oncology · Eugene, ORNPI 1063437127

Payments from drug & device makers

What this record shows

The money is spread across several categories — speaking fees (55.9%), consulting fees and travel and lodging — rather than concentrated in one kind of arrangement. Merck accounts for 80.9% of it on its own, with 11 other manufacturers making up the rest. Reporting peaked in 2019 at $21,146 and has fallen 83.9% since, to $3,395 in 2025. Among gynecologic oncology clinicians in OR with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$40,823in general payments, 2019–2025

Across 99 payments — averaging $412.36 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Merck$33K
  • Intuitive Surgical$2K
  • AstraZeneca$2K
  • Eisai Inc.$2K
  • Myriad Genetic Laboratories, Inc.$343
  • GSK$292
  • plus $530 from 6 others
$555,450in research payments, 2019–2025

Across 10 payments — averaging $55,545 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Merck$555K

What the payments were for

  • Consulting fees$9,33023%
  • Speaking & faculty fees$22,81456%
  • Travel & lodging$5,11613%
  • Food & beverage$3,1338%
  • Education$1760%
  • Gifts$2541%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Merck36$33,032
Intuitive Surgical43$2,423
AstraZeneca3$2,149
Eisai Inc.1$2,055
Myriad Genetic Laboratories, Inc.4$343
GSK3$292
Foundation Medicine, Inc.2$131
Gen-probe Sales & Service, Inc.1$122
Seagen Inc.1$96
Baxter Healthcare3$93
Tempus AI, Inc1$52
AbbVie1$35

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$40,823 in reported general payments places this provider in the 95th percentile of 25 gynecologic oncology providers in Oregon.

See all gynecologic oncology providers in Oregon

Medicare billing

Part B allowed, 2024
$430,056
Medicare patients
239
Services billed
20,853

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban21$12,259
Estradiol18$2,220
Dexamethasone16$556
Anastrozole45$549
Prochlorperazine Maleate21$265
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen51$247
Ondansetron Hcl23$236
Oxycodone Hcl13$61
Lorazepam14$38

Paid to pharmacies, not to this prescriber.

Other gynecologic oncology in Eugene

See the full list for Oregon

Where these figures come from

Is this you, or does something look wrong? →